Charles River Laboratories International, Inc. (CRL) stock
CRLNYSEServices-Commercial Physical & Biological ResearchFiscal year ends December 27
Financials through Q2 FY2026, quarter ended Jun 27, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30225% above fair value
$332.16−3.36 (-1.00%)
Close on Nov 17, 2026Market cap $15.86BP/E –Yield –
Charles River Laboratories International total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Charles River Laboratories International's total debt was $2.63B at Jun 27, 2026. For fiscal 2025 it was $2.14B, down 4.6% from the year before. Over ten years it grew 9.8% a year on average. The highest annual figure on record is $2.71B in fiscal 2022.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 27, 2025 | $2.14B | -4.6% |
| FY2024 | Dec 28, 2024 | $2.24B | -15.5% |
| FY2023 | Dec 30, 2023 | $2.65B | -2.2% |
| FY2022 | Dec 31, 2022 | $2.71B | +1.7% |
| FY2021 | Dec 25, 2021 | $2.66B | +34.7% |
| FY2020 | Dec 26, 2020 | $1.98B | +4.9% |
| FY2019 | Dec 28, 2019 | $1.89B | +13.2% |
| FY2018 | Dec 29, 2018 | $1.66B | +48.6% |
| FY2017 | Dec 30, 2017 | $1.12B | -7.6% |
| FY2016 | Dec 31, 2016 | $1.21B | +45.0% |
| FY2015 | Dec 26, 2015 | $836.23M | +10.9% |
| FY2014 | Dec 27, 2014 | $753.75M | +13.7% |
| FY2013 | Dec 28, 2013 | $663.05M | -0.5% |
| FY2012 | Dec 29, 2012 | $666.45M | -7.2% |
| FY2011 | Dec 31, 2011 | $717.90M | +2.4% |
| FY2010 | Dec 25, 2010 | $700.75M | +42.2% |
| FY2009 | Dec 26, 2009 | $492.83M | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 27, 2026 | $2.63B | +12.6% |
| Q1 FY2026 | Mar 28, 2026 | $2.67B | +6.3% |
| Q4 FY2025 | Dec 27, 2025 | $2.14B | -4.6% |
| Q3 FY2025 | Sep 27, 2025 | $2.19B | -6.1% |
| Q2 FY2025 | Jun 28, 2025 | $2.33B | -3.2% |
| Q1 FY2025 | Mar 29, 2025 | $2.51B | -5.6% |
| Q4 FY2024 | Dec 28, 2024 | $2.24B | -15.5% |
| Q3 FY2024 | Sep 28, 2024 | $2.33B | -7.5% |
| Q2 FY2024 | Jun 29, 2024 | $2.41B | -10.1% |
| Q1 FY2024 | Mar 30, 2024 | $2.66B | -3.2% |
| Q4 FY2023 | Dec 30, 2023 | $2.65B | -2.2% |
| Q3 FY2023 | Sep 30, 2023 | $2.52B | -14.4% |
| Q2 FY2023 | Jul 1, 2023 | $2.68B | -10.6% |
| Q1 FY2023 | Apr 1, 2023 | $2.75B | +2.7% |
| Q4 FY2022 | Dec 31, 2022 | $2.71B | +1.7% |
| Q3 FY2022 | Sep 24, 2022 | $2.94B | +1.5% |
| Q2 FY2022 | Jun 25, 2022 | $3.00B | +9.9% |
| Q1 FY2022 | Mar 26, 2022 | $2.68B | +21.5% |
| Q4 FY2021 | Dec 25, 2021 | $2.66B | +34.7% |
| Q3 FY2021 | Sep 25, 2021 | $2.89B | +43.7% |
| Q2 FY2021 | Jun 26, 2021 | $2.73B | +20.8% |
| Q1 FY2021 | Mar 27, 2021 | $2.20B | -7.1% |
| Q4 FY2020 | Dec 26, 2020 | $1.98B | +4.9% |
| Q3 FY2020 | Sep 26, 2020 | $2.01B | +5.2% |
| Q2 FY2020 | Jun 27, 2020 | $2.26B | +9.0% |
| Q1 FY2020 | Mar 28, 2020 | $2.37B | +51.1% |
| Q4 FY2019 | Dec 28, 2019 | $1.89B | +13.2% |
| Q3 FY2019 | Sep 28, 2019 | $1.91B | +14.5% |
| Q2 FY2019 | Jun 29, 2019 | $2.07B | +14.1% |
| Q1 FY2019 | Mar 30, 2019 | $1.57B | +41.4% |
| Q4 FY2018 | Dec 29, 2018 | $1.66B | +48.6% |
| Q3 FY2018 | Sep 29, 2018 | $1.67B | +44.2% |
| Q2 FY2018 | Jun 30, 2018 | $1.82B | +62.1% |
| Q1 FY2018 | Mar 31, 2018 | $1.11B | -5.5% |
| Q4 FY2017 | Dec 30, 2017 | $1.12B | -7.6% |
| Q3 FY2017 | Sep 30, 2017 | $1.16B | -6.5% |
| Q2 FY2017 | Jul 1, 2017 | $1.12B | – |
| Q1 FY2017 | Apr 1, 2017 | $1.17B | – |
| Q4 FY2016 | Dec 31, 2016 | $1.21B | – |
| Q3 FY2016 | Sep 24, 2016 | $1.24B | – |
See a number that looks wrong?